Guanmei Cao1, Richard A E Edden2,3, Fei Gao1, Hao Li4, Tao Gong1, Weibo Chen5, Xiaohui Liu6, Guangbin Wang7, Bin Zhao1. 1. Shandong Medical Imaging Research Institute, Shandong University, Jinan, 250021, Shandong, China. 2. Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. 3. FM Kirby Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, 21287, USA. 4. Air Force General Hospital PLA, Beijing, 100142, China. 5. Philips Healthcare, Shanghai, China. 6. Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, Shandong, China. 7. Shandong Medical Imaging Research Institute, Shandong University, Jinan, 250021, Shandong, China. wgb7932596@hotmail.com.
Abstract
OBJECTIVES: To investigate if brain gamma-aminobutyric acid (GABA) levels in patients with relapsing-remitting multiple sclerosis (RRMS) are abnormal compared with healthy controls, and their relationship to cognitive function in RRMS. METHODS: Twenty-eight RRMS patients and twenty-six healthy controls underwent magnetic resonance spectroscopy (MRS) at 3-T to detect GABA signals from posterior cingulate cortex (PCC), medial prefrontal cortex (mPFC) and left hippocampus using the 'MEGAPoint Resolved Spectroscopy Sequence' (MEGA-PRESS) technique. All subjects also underwent a cognitive assessment. RESULTS: In RRMS patients, GABA+ were lower in the PCC (p = 0.036) and left hippocampus (p = 0.039) compared with controls, decreased GABA+ in the PCC and left hippocampus were associated with specific cognitive functions (r = -0.452, p = 0.016 and r = 0.451, p = 0.016 respectively); GABA+ in the mPFC were not significantly decreased or related to any cognitive scores (p > 0.05). CONCLUSIONS: This study demonstrates that abnormalities of the GABAergic system may be present in the pathogenesis of RRMS and suggests a potential link between regional GABA levels and cognitive impairment in patients with RRMS. KEY POINTS: • GABA levels may decrease in patients with RRMS. • Lower GABA levels correlated with worse cognitive performance in patients with RRMS. • Dysfunctional GABAergic neurotransmission may have a role in cognitive impairment in RRMS.
OBJECTIVES: To investigate if brain gamma-aminobutyric acid (GABA) levels in patients with relapsing-remitting multiple sclerosis (RRMS) are abnormal compared with healthy controls, and their relationship to cognitive function in RRMS. METHODS: Twenty-eight RRMS patients and twenty-six healthy controls underwent magnetic resonance spectroscopy (MRS) at 3-T to detect GABA signals from posterior cingulate cortex (PCC), medial prefrontal cortex (mPFC) and left hippocampus using the 'MEGAPoint Resolved Spectroscopy Sequence' (MEGA-PRESS) technique. All subjects also underwent a cognitive assessment. RESULTS: In RRMS patients, GABA+ were lower in the PCC (p = 0.036) and left hippocampus (p = 0.039) compared with controls, decreased GABA+ in the PCC and left hippocampus were associated with specific cognitive functions (r = -0.452, p = 0.016 and r = 0.451, p = 0.016 respectively); GABA+ in the mPFC were not significantly decreased or related to any cognitive scores (p > 0.05). CONCLUSIONS: This study demonstrates that abnormalities of the GABAergic system may be present in the pathogenesis of RRMS and suggests a potential link between regional GABA levels and cognitive impairment in patients with RRMS. KEY POINTS: • GABA levels may decrease in patients with RRMS. • Lower GABA levels correlated with worse cognitive performance in patients with RRMS. • Dysfunctional GABAergic neurotransmission may have a role in cognitive impairment in RRMS.
Authors: Frederic Boy; C John Evans; Richard A E Edden; Krish D Singh; Masud Husain; Petroc Sumner Journal: Curr Biol Date: 2010-09-30 Impact factor: 10.834
Authors: M S Milak; C J Proper; S T Mulhern; A L Parter; L S Kegeles; R T Ogden; X Mao; C I Rodriguez; M A Oquendo; R F Suckow; T B Cooper; J G Keilp; D C Shungu; J J Mann Journal: Mol Psychiatry Date: 2015-08-18 Impact factor: 15.992
Authors: Vincent C Lombardi; Kenny L De Meirleir; Krishnamurthy Subramanian; Sam M Nourani; Ruben K Dagda; Shannon L Delaney; András Palotás Journal: J Nutr Biochem Date: 2018-04-19 Impact factor: 6.048
Authors: J Singh; M Cerghet; L M Poisson; I Datta; K Labuzek; H Suhail; R Rattan; Shailendra Giri Journal: J Neuroimmune Pharmacol Date: 2018-10-12 Impact factor: 4.147
Authors: Siwen Kang; Lingling Liu; Tingting Wang; Matthew Cannon; Penghui Lin; Teresa W-M Fan; David A Scott; Hsin-Jung Joyce Wu; Andrew N Lane; Ruoning Wang Journal: Nat Metab Date: 2022-10-03
Authors: Eva Heckova; Bernhard Strasser; Gilbert J Hangel; Michal Považan; Assunta Dal-Bianco; Paulus S Rommer; Petr Bednarik; Stephan Gruber; Fritz Leutmezer; Hans Lassmann; Siegfried Trattnig; Wolfgang Bogner Journal: Invest Radiol Date: 2019-04 Impact factor: 6.016